Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.
作者信息
Bröckelmann P J, Müller H, Fuchs M, Gillessen S, Eichenauer D A, Borchmann S, Robertz A S, Behringer K, Welters J, Ferdinandus J, Böll B, Tharmaseelan H, Yang X, Kobe C, Eich H -T, Baues C, Klapper W, Borchmann P, von Tresckow B
机构信息
University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) and German Hodgkin Study Group (GHSG), Cologne, Germany.
Merck & Co., Inc, Kenilworth, NJ, USA.
出版信息
Leukemia. 2025 Apr;39(4):988-990. doi: 10.1038/s41375-025-02567-w. Epub 2025 Mar 24.
Abstract
摘要
相似文献
1
Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.复发霍奇金淋巴瘤治疗后的无进展生存期和总生存期的相关性：德国霍奇金研究组（GHSG）随机试验的个体患者数据分析
Leukemia. 2025 Apr;39(4):988-990. doi: 10.1038/s41375-025-02567-w. Epub 2025 Mar 24.
2
Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.更正：复发霍奇金淋巴瘤治疗后无进展生存期与总生存期的相关性：德国霍奇金淋巴瘤研究组（GHSG）随机试验的个体患者数据分析
Leukemia. 2025 May;39(5):1274. doi: 10.1038/s41375-025-02597-4.
3
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials.霍奇金淋巴瘤患者无进展生存期与总生存期的相关性：来自德国霍奇金淋巴瘤研究组（GHSG）随机试验的个体患者数据综合分析
Ann Oncol. 2025 Apr;36(4):393-402. doi: 10.1016/j.annonc.2024.12.009. Epub 2024 Dec 18.
4
The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.德国霍奇金淋巴瘤研究组（GHSG）内放射治疗质量保证计划的发展。放疗参考小组的介绍、持续工作及成果。
Strahlenther Onkol. 2005 Sep;181(9):557-66. doi: 10.1007/s00066-005-1437-0.
5
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).利妥昔单抗用于复发的淋巴细胞为主型霍奇金淋巴瘤：德国霍奇金淋巴瘤研究组（GHSG）一项2期试验的长期结果
Blood. 2008 Jan 1;111(1):109-11. doi: 10.1182/blood-2007-03-078725. Epub 2007 Oct 15.
6
The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.德国霍奇金淋巴瘤研究组风险模型对接受自体干细胞移植后放疗的霍奇金淋巴瘤患者有用。
Cancer Radiother. 2019 Sep;23(5):378-384. doi: 10.1016/j.canrad.2019.02.002. Epub 2019 Jun 6.
7
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.结节性淋巴细胞为主型霍奇金淋巴瘤患者在 HD7 至 HD15 试验中的长期随访：德国霍奇金研究组的报告。
J Clin Oncol. 2020 Mar 1;38(7):698-705. doi: 10.1200/JCO.19.00986. Epub 2019 Oct 18.
8
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.复发和难治性结节性淋巴细胞为主型霍奇金淋巴瘤：德国霍奇金研究组的分析。
Blood. 2018 Oct 4;132(14):1519-1525. doi: 10.1182/blood-2018-02-836437. Epub 2018 Jul 31.
9
Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group.霍奇金淋巴瘤的生活质量评估：一种全新的综合方法。来自欧洲癌症研究与治疗组织/成人淋巴瘤研究组（EORTC/GELA）及德国霍奇金淋巴瘤研究组（GHSG）试验的初步经验。欧洲癌症研究与治疗组织淋巴瘤协作组、成人淋巴瘤研究组及德国霍奇金淋巴瘤研究组
Ann Oncol. 1998;9 Suppl 5:S147-54. doi: 10.1093/annonc/9.suppl_5.s147.
10
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).早期预后不良霍奇金淋巴瘤患者的强化治疗：德国霍奇金研究组（GHSG HD14）随机、国际 3 期试验的长期随访结果
Lancet Haematol. 2021 Apr;8(4):e278-e288. doi: 10.1016/S2352-3026(21)00029-6.
本文引用的文献
1
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials.霍奇金淋巴瘤患者无进展生存期与总生存期的相关性：来自德国霍奇金淋巴瘤研究组（GHSG）随机试验的个体患者数据综合分析
Ann Oncol. 2025 Apr;36(4):393-402. doi: 10.1016/j.annonc.2024.12.009. Epub 2024 Dec 18.
2
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.不可调和的差异：缓解率、无进展生存期和总生存期之间的脱节
J Clin Oncol. 2023 May 20;41(15):2706-2712. doi: 10.1200/JCO.23.00225. Epub 2023 Mar 17.
3
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.新型药物时代自体移植后复发/难治性霍奇金淋巴瘤患者结局的改善。
Blood. 2023 Jun 1;141(22):2727-2737. doi: 10.1182/blood.2022018827.
4
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.当代一线治疗后复发/难治性霍奇金淋巴瘤患者的临床结局：德国霍奇金研究组分析。
Leukemia. 2022 Mar;36(3):772-780. doi: 10.1038/s41375-021-01442-8. Epub 2021 Oct 9.
5
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review.无进展生存期作为肿瘤学试验中总生存期的替代指标：方法学系统评价。
Br J Cancer. 2020 May;122(11):1707-1714. doi: 10.1038/s41416-020-0805-y. Epub 2020 Mar 26.
6
Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's τ.使用 Kendall's τ 定量评估肿瘤学试验中无进展生存期和总生存期之间的关联。
Stat Med. 2019 Feb 28;38(5):703-719. doi: 10.1002/sim.8001. Epub 2018 Oct 12.
7
Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.德国、法国和英国经典霍奇金淋巴瘤一线治疗的患者和医生偏好。
Br J Haematol. 2019 Jan;184(2):202-214. doi: 10.1111/bjh.15566. Epub 2018 Sep 21.
8
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.自体造血干细胞移植治疗复发或难治性霍奇金淋巴瘤后的生存风险因素和预后评分。
Ann Oncol. 2017 Jun 1;28(6):1352-1358. doi: 10.1093/annonc/mdx072.
9
Estimating the correlation of bivariate failure times under censoring.在删失数据下估计二元失效时间的相关性。
Stat Med. 2013 Nov 30;32(27):4781-90. doi: 10.1002/sim.5874. Epub 2013 Jun 17.
10
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.复发霍奇金淋巴瘤患者的化疗剂量强度。
J Clin Oncol. 2010 Dec 1;28(34):5074-80. doi: 10.1200/JCO.2010.30.5771. Epub 2010 Oct 25.
Zotero 插件